Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Total Liabilities (2020 - 2025)

Bolt Biotherapeutics' Total Liabilities history spans 6 years, with the latest figure at $33.0 million for Q3 2025.

  • For Q3 2025, Total Liabilities fell 11.66% year-over-year to $33.0 million; the TTM value through Sep 2025 reached $33.0 million, down 11.66%, while the annual FY2024 figure was $42.4 million, 9.8% down from the prior year.
  • Total Liabilities for Q3 2025 was $33.0 million at Bolt Biotherapeutics, down from $36.7 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $58.6 million in Q3 2021 and bottomed at $21.4 million in Q1 2021.
  • The 5-year median for Total Liabilities is $47.1 million (2023), against an average of $45.6 million.
  • The largest annual shift saw Total Liabilities plummeted 60.56% in 2021 before it surged 154.33% in 2022.
  • A 5-year view of Total Liabilities shows it stood at $57.6 million in 2021, then decreased by 2.25% to $56.3 million in 2022, then dropped by 16.44% to $47.0 million in 2023, then fell by 9.8% to $42.4 million in 2024, then fell by 22.35% to $33.0 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Total Liabilities are $33.0 million (Q3 2025), $36.7 million (Q2 2025), and $39.1 million (Q1 2025).